Alterity Therapeutics (ASX:ATH) Other Long-Term Liabilities: A$0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:ATH Alterity Therapeutics Ltd ASX:ATH
28 GF Score
Price A$0.51
View Full Analysis

What is Alterity Therapeutics Other Long-Term Liabilities?

Alterity Therapeutics ASX:ATH -3.77% 28 Other Long-Term Liabilities is A$0.00 Mil as of Dec. 2025. GuruFocus rates ASX:ATH with a GF Score™ of 28/100.

Alterity Therapeutics's other long-term liabilities for the quarter that ended in Dec. 2025 was A$0.00 Mil.

Alterity Therapeutics's quarterly other long-term liabilities increased from Jun. 2025 (A$-0.00 Mil) to Sep. 2025 (A$0.00 Mil) and increased from Sep. 2025 (A$0.00 Mil) to Dec. 2025 (A$0.00 Mil).

Alterity Therapeutics's annual other long-term liabilities increased from Jun. 2023 (A$0.00 Mil) to Jun. 2024 (A$0.00 Mil) but then declined from Jun. 2024 (A$0.00 Mil) to Jun. 2025 (A$-0.00 Mil).

Alterity Therapeutics Other Long-Term Liabilities Related Terms

Alterity Therapeutics Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Alterity Therapeutics's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alterity Therapeutics Other Long-Term Liabilities Chart

Alterity Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Other Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.00 -0.00 0.00 0.00 -0.00

Alterity Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -0.00 0.00 0.00 0.00
ASX:ATH
28GF Score
Alterity Therapeutics Ltd ASX:ATH
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alterity Therapeutics Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of A$0.00 Mil mean?
Alterity Therapeutics (ASX:ATH) has a Other Long-Term Liabilities of A$0.00 Mil as of Dec. 2025. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Alterity Therapeutics and its competitors.
Is Alterity Therapeutics' Other Long-Term Liabilities too high?
Alterity Therapeutics' current Other Long-Term Liabilities is A$0.00 Mil. Overall, Alterity Therapeutics has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Alterity Therapeutics' Other Long-Term Liabilities compare to VRTX and REGN?
Alterity Therapeutics' Other Long-Term Liabilities of A$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Biotechnology company?
A good Other Long-Term Liabilities depends on the Biotechnology industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Alterity Therapeutics and its competitors. Alterity Therapeutics's current Other Long-Term Liabilities is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alterity Therapeutics stock overvalued right now?
Alterity Therapeutics (ASX:ATH) has a current Other Long-Term Liabilities of A$0.00 Mil. The current Other Long-Term Liabilities is A$0.00 Mil. Alterity Therapeutics' overall GF Score™ is 28/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Alterity Therapeutics (ASX:ATH), the current Other Long-Term Liabilities is A$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Alterity Therapeutics Business Description

Other Exchanges ATHE:USAPBN:Germany
Address 350 Collins Street, Suite 4, Level 14, Melbourne, VIC, AUS, 3000
Alterity Therapeutics Ltd is a clinical-stage biotechnology company focused on neurodegenerative diseases and the creation of a chemical library of proprietary molecules. Its research and clinical development efforts are focused on Parkinson's disease and related disorders, where it is identifying and developing novel compounds that address the underlying pathology of these disorders by binding and redistributing excess labile iron, reducing alpha-synuclein aggregation, and rescuing neurons in the brain. Its pipeline programs are ATH434-201, ATH434-202, bioMUSE, ATH434, and Drug Discovery. The Group operated in one segment, research and development into Parkinsonian and other neurodegenerative disorders.
28GF Score

Get the complete analysis for ASX:ATH

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.51
Price